Bull Run
Home
Watchlist
Bull Run

India's AI-powered stock screener for NSE & BSE. 5,000+ stocks with fundamentals and real-time analysis.

[email protected]

Navigate

  • Home
  • Smart Screener
  • Stock Battle Arena
  • Watchlist
  • Go Premium

Tools

  • Advanced Stock Screening
  • Stock Comparison Tool
  • Personal Watchlist
  • Ask AI Assistant
  • Browse All Stocks
  • IPO GMP Tracker
  • Market News & Blog

Indices

  • All Indices
  • Nifty 50 Stocks
  • Sensex Stocks
  • Nifty Bank
  • Nifty IT
  • Nifty Pharma
  • Nifty Midcap 100

Screeners

  • Top Dividend Stocks
  • Debt Free Stocks
  • Undervalued Stocks
  • High ROE Stocks
  • Low PE Stocks
  • Top Rated Stocks
  • Large Cap Stocks
  • Compare Stocks
  • Browse by Sector

Browse Stocks by Sector

View All →
Non Banking Financial Company (NBFC)PharmaceuticalsComputers - Software & ConsultingIndustrial ProductsCivil ConstructionAuto Components & EquipmentsSpecialty ChemicalsOther Financial ServicesIT Enabled ServicesPackagingHotels & ResortsCommodity ChemicalsOther Electrical EquipmentGarments & ApparelsPaper & Paper ProductsSoftware ProductsPackaged FoodsCement & Cement ProductsSugarHeavy Electrical EquipmentHospitalEdible OilPower GenerationHealthcare Service Provider
© 2026 Bull Run. All rights reserved.
AboutBlogPrivacy PolicyTerms of Service

Disclaimer: Ratings and scores are generated algorithmically from publicly available market data for educational and informational purposes only. They do not constitute investment advice or solicitation to buy/sell securities. Bull Run is not a SEBI-registered Research Analyst or Investment Adviser.

HomeAll SectorsPharmaceuticals

Pharmaceuticals Stocks

208 companies · NSE & BSE · Updated daily

About the Pharmaceuticals Sector

The Indian pharmaceutical sector, a consistent performer, is showing signs of renewed strength. Driven by domestic demand, export opportunities, and a focus on specialty generics, many Indian pharma players are poised for growth. Bull Run's analysis highlights stocks exhibiting robust financial health and promising valuations.

Indian pharmaceutical companies are increasingly leveraging their R&D capabilities and manufacturing prowess to capture global market share, particularly in regulated markets like the US. Favorable regulatory pathways, such as USFDA approvals and ANDA filings, are critical indicators of future revenue streams. While the sector grapples with pricing pressures in certain segments, a strategic shift towards complex generics and contract development and manufacturing (CDMO) services is proving effective. Diversification across therapeutic areas and geographies mitigates risk and enhances long-term sustainability.

What to Watch

Monitor USFDA inspection outcomes and the pace of new product approvals. Keep an eye on the evolving regulatory landscape in key export markets and the competitive intensity in the domestic formulations business. Increasing R&D spends and CDMO order books are positive signals for future growth.

Related Research

Compare Pharma Stocks →High ROE Pharma Stocks →Nifty Pharma Index →Pharma Sector Analysis →Screen Pharmaceuticals →

Frequently Asked Questions

What are the key drivers for the Indian Pharma sector's bull run?

Key drivers include strong domestic demand, increasing export opportunities in regulated markets, government initiatives like PLI schemes, and a growing focus on specialty and complex generics. The CDMO segment is also a significant growth catalyst.

How important are USFDA approvals for Indian pharma stocks?

USFDA approvals are crucial as they grant access to the lucrative US market, which is the largest pharmaceutical market globally. Successful approvals and inspections indicate product quality and compliance, directly impacting revenue potential and investor confidence.

What is the role of R&D and innovation in this sector?

R&D and innovation are vital for developing differentiated products, complex generics, and biosimilars. Companies investing significantly in R&D are better positioned to command higher margins and gain a competitive edge, especially in innovation-driven segments.

How does the Bull Run score assess pharma stocks?

The Bull Run score evaluates pharma stocks based on financial health (ROE, debt-to-equity), valuation metrics (P/E), and growth prospects. It aims to identify fundamentally sound companies trading at reasonable valuations within the sector.

Pharmaceuticals Stocks — Page 3 of 7

#CompanySymbolPriceChangeMarket Cap
61Unichem Laboratories Ltd
FinancialsP/EResults
UNICHEMLAB₹449.45+0.69%₹3.2K Cr
62Sms Pharmaceuticals Ltd
FinancialsP/EResults
SMSPHARMA₹375.95-0.12%₹2.9K Cr
63Hikal Ltd
FinancialsP/EResults
HIKAL₹189.96+0.14%₹2.8K Cr
64IOL Chemicals and Pharmaceuticals Ltd
FinancialsP/EResults
IOLCP₹125.10-0.76%₹2.6K Cr
65Indoco Remedies Ltd
FinancialsP/EResults
INDOCO₹231.23-0.75%₹2.4K Cr
66Morepen Laboratories Ltd
FinancialsP/EResults
MOREPENLAB₹51.48-1.53%₹2.4K Cr
67Solara Active Pharma Sciences Ltd
FinancialsP/EResults
SOLARA₹581.45-1.31%₹2.3K Cr
68Panacea Biotec Ltd
FinancialsP/EResults
PANACEABIO₹532.20-2.34%₹2.2K Cr
69Novartis India Ltd
FinancialsP/EResults
NOVARTIND₹1365.60+3.18%₹2.0K Cr
70Amrutanjan Health Care Ltd
FinancialsP/EResults
AMRUTANJAN₹533.75-1.39%₹2.0K Cr
71BETA Technologies, Inc Class A Common Stock
FinancialsP/EResults
BETA₹1661.10+0.00%₹1.7K Cr
72Shukra Pharmaceuticals Ltd
FinancialsP/EResults
SHUKRAPHAR₹31.18+0.10%₹1.7K Cr
73Windlas Biotech Ltd
FinancialsP/EResults
WINDLAS₹817.00-1.47%₹1.7K Cr
74Bliss GVS Pharma Ltd
FinancialsP/EResults
BLISSGVS₹474.85+5.08%₹1.6K Cr
75Syncom Formulations India Ltd
FinancialsP/EResults
SYNCOMF₹14.22-0.97%₹1.5K Cr
76Jagsonpal Pharmaceuticals Ltd
FinancialsP/EResults
JAGSNPHARM₹209.19-0.03%₹1.5K Cr
77Sigachi Industries Ltd
FinancialsP/EResults
SIGACHI₹21.71+2.55%₹1.4K Cr
78Hester Biosciences Ltd
FinancialsP/EResults
HESTERBIO₹2052.60-0.09%₹1.4K Cr
79Bajaj Healthcare Ltd
FinancialsP/EResults
BAJAJHCARE₹299.20-1.03%₹1.4K Cr
80Lincoln Pharmaceuticals Ltd
FinancialsP/EResults
LINCOLN₹629.75-2.52%₹1.0K Cr
81Venus Remedies Ltd
FinancialsP/EResults
VENUSREM₹1774.50-5.00%₹1.0K Cr
82Themis Medicare Ltd
FinancialsP/EResults
THEMISMED₹102.64+1.12%₹1.0K Cr
83Kwality Pharmaceuticals Ltd
FinancialsP/EResults
KPL₹2360.80-2.77%₹1.0K Cr
84Fredun Pharmaceuticals Ltd
FinancialsP/EResults
FREDUN₹2610.15+3.06%₹0.9K Cr
85Wanbury Ltd
FinancialsP/EResults
WANBURY₹267.95-0.20%₹0.9K Cr
86Anlon Healthcare
FinancialsP/EResults
AHCL₹15.99-0.50%₹0.9K Cr
87Sakar Healthcare Ltd
FinancialsP/EResults
SAKAR₹801.40-2.62%₹0.9K Cr
88Remus Pharmaceuticals Ltd
FinancialsP/EResults
REMUS₹764.80+1.15%₹0.8K Cr
89NGL Fine Chem Ltd
FinancialsP/EResults
NGLFINE₹2930.30-1.56%₹0.8K Cr
90ACCENTMICST
FinancialsP/EResults
ACCENTMIC₹267.00+0.00%₹0.8K Cr
Previous
1234567
Next
Page 3 of 7 (208 stocks)
← View All Sectors